Stemline Therapeutics (STML) EPS Estimated At $-0.50, Gerdau SA (GGB) SI Increased By 6.43%

July 20, 2017 - By Stephen Andrade

Analysts expect Stemline Therapeutics Inc (NASDAQ:STML) to report $-0.50 EPS on August, 3.They anticipate $0.02 EPS change or 3.85% from last quarter’s $-0.52 EPS. After having $-0.67 EPS previously, Stemline Therapeutics Inc’s analysts see -25.37% EPS growth. The stock decreased 1.99% or $0.2 during the last trading session, reaching $9.85. About shares traded. Stemline Therapeutics Inc (NASDAQ:STML) has risen 52.65% since July 20, 2016 and is uptrending. It has outperformed by 35.95% the S&P500.

Gerdau SA (NYSE:GGB) had an increase of 6.43% in short interest. GGB’s SI was 25.46 million shares in July as released by FINRA. Its up 6.43% from 23.92 million shares previously. With 7.96 million avg volume, 3 days are for Gerdau SA (NYSE:GGB)’s short sellers to cover GGB’s short positions. The stock increased 2.65% or $0.09 during the last trading session, reaching $3.48. About shares traded. Gerdau SA (ADR) (NYSE:GGB) has risen 83.44% since July 20, 2016 and is uptrending. It has outperformed by 66.74% the S&P500.

Gerdau S.A. is a manufacturer of long steel in the North and South America. The company has market cap of $5.98 billion. The Firm is engaged in the production and commercialization of steel products in general, through its mills located in Argentina, Brazil, Canada, Chile, Colombia, Spain, the United States, Guatemala, India, Mexico, Peru, the Dominican Republic, Uruguay and Venezuela. It currently has negative earnings. The Company’s divisions are Brazil Operations, which includes activities of steel and iron ore in Brazil, except Special Steels, and the operation of metallurgical coal and coke in Colombia; North America Operations, which includes all activities in North America, except those of Mexico and Special Steels; South America Operations, which includes activities in South America, except Brazil and the operation of metallurgical coal and coke in Colombia, and Special Steel Operations, including special steel activities in Brazil, Spain, the United States and India.

Among 5 analysts covering Gerdau (NYSE:GGB), 3 have Buy rating, 2 Sell and 0 Hold. Therefore 60% are positive. Gerdau had 6 analyst reports since August 10, 2015 according to SRatingsIntel. The firm has “Outperform” rating by Credit Suisse given on Thursday, August 4. Goldman Sachs initiated it with “Buy” rating and $2.30 target in Monday, August 10 report. The stock has “Underperform” rating by Bank of America on Monday, February 22. Scotia Capital downgraded Gerdau SA (ADR) (NYSE:GGB) on Tuesday, October 25 to “Underperform” rating. The rating was upgraded by Morgan Stanley to “Overweight” on Thursday, August 18.

Among 4 analysts covering Stemline Therapeutics Inc (NASDAQ:STML), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Stemline Therapeutics Inc had 7 analyst reports since November 10, 2015 according to SRatingsIntel. Cowen & Co maintained the shares of STML in report on Wednesday, June 14 with “Buy” rating. The rating was maintained by Cowen & Co with “Buy” on Friday, June 23. Wedbush maintained Stemline Therapeutics Inc (NASDAQ:STML) on Monday, February 6 with “Outperform” rating. Jefferies maintained it with “Buy” rating and $1600 target in Monday, June 26 report. The stock of Stemline Therapeutics Inc (NASDAQ:STML) has “Buy” rating given on Monday, June 26 by H.C. Wainwright.

Since February 16, 2017, it had 0 insider purchases, and 8 selling transactions for $332,397 activity. Hoberman Kenneth sold $9,681 worth of Stemline Therapeutics Inc (NASDAQ:STML) on Thursday, February 16. 6,486 shares were sold by Gionco David, worth $45,327. Bergstein Ivan sold $23,446 worth of stock or 3,652 shares.

Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on discovering, acquiring, developing and commercializing oncology therapeutics. The company has market cap of $243.75 million. The Firm is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. It currently has negative earnings. SL-401 is a targeted therapy directed to the interleukin-3 receptor (CD123), present on a range of hematologic cancers.

Investors sentiment decreased to 1.9 in Q4 2016. Its down 0.05, from 1.95 in 2016Q3. It dived, as 7 investors sold Stemline Therapeutics Inc shares while 14 reduced holdings. 14 funds opened positions while 26 raised stakes. 9.13 million shares or 9.47% more from 8.34 million shares in 2016Q3 were reported. Rhumbline Advisers accumulated 0% or 19,231 shares. Credit Suisse Ag holds 0% or 11,483 shares. Ny State Common Retirement Fund reported 31,200 shares or 0% of all its holdings. Tiaa Cref Mgmt Ltd Liability Corp has 0% invested in Stemline Therapeutics Inc (NASDAQ:STML). Oxford Asset has 0.02% invested in Stemline Therapeutics Inc (NASDAQ:STML). California Public Employees Retirement Systems owns 31,100 shares. Blackrock Institutional Na holds 0% or 276,656 shares in its portfolio. State Street Corporation holds 0% of its portfolio in Stemline Therapeutics Inc (NASDAQ:STML) for 251,804 shares. Blackrock holds 3,584 shares or 0% of its portfolio. California State Teachers Retirement Systems reported 34,749 shares stake. 164,302 are owned by Millennium Management Ltd Liability Com. Bailard Inc invested in 0.12% or 123,785 shares. Dimensional Fund Advsrs Lp owns 79,719 shares or 0% of their US portfolio. Creative Planning invested in 1,150 shares. Bogle Investment L P De holds 0.07% of its portfolio in Stemline Therapeutics Inc (NASDAQ:STML) for 94,945 shares.